Therapies for pulmonary fibrosis and other diseases
Fibrosis is associated with 30 – 45% of deaths in US, and a clearly undermet medical need. Prosia is an early stage company developing therapeutics for pulmonary fibrosis, as well as other fibrosing diseases. We also found that one of our lead compounds inhibits cytokine storm and lung damage in a mouse model of COVID-19-type lung damage. We have a compelling target with excellent target rationale and strong patent applications for fibrosis and a variety of other diseases. Our lead compounds show outstanding efficacy, and a surrogate marker make this platform a very promising approach to therapeutics.